Oy Vey, Teva!

Things appear to be going from bad to worse at Teva, which is giving the strong impression of being in meltdown. One can only hope that the recent Q2 results, which featured an eye-watering $6.1bn write-down of the company’s recently-acquired Actavis generics assets, mark…

Read More

Biosimilars: The five stages of grief

According to the Swiss psychiatrist Elisabeth Kübler-Ross, grief has five stages: denial, anger, bargaining, depression and acceptance. Although the development of biosimilars should not be an inherently grief-stricken business, it nevertheless appears to be closely following this path, certainly from the perspective of the…

Read More

Goodness gracious me! Time for a management change at Teva

 

The news earlier this week that Siggi Olafsson is leaving Teva, to be succeeded by Dipankar Bhattacharjee (currently head of Teva Generics Europe) comes as something of a surprise, to say the least. As the architect of Teva’s long drawn-out purchase of Allergan’s generics…

Read More

Hartmut Retzlaff falls victim to barbarian hordes

The announcement today that Hartmut Retzlaff has stepped down as CEO of Stada ‘due to a serious long-term illness’ comes as something of a surprise, but the reasons are not hard to discern. For weeks, activist investors in the form of a group called…

Read More

Oh My: Mylan, Meda and muddle

Mylan’s announcement last month that it has agreed to buy Meda for $9.9bn was greeted with a distinct lack of enthusiasm by the stock market, which marked the company’s shares down 18% the following day. This was a reversal from the recent norm in…

Read More

Into the void: All change in UK generics in 2016

Teva’s announcement last year that it was to acquire Allergan’s generic assets (‘Actavis’), came as a total surprise to the market. All the more so since Teva was, at the time, in hot pursuit of Mylan. It was particularly startling news in the UK,…

Read More

Goodbye sanofi, hello Zentiva

For us, the big headline from sanofi’s recent ‘meet the management’ day in Paris was the company’s announcement that it was reviewing the future of its European generics operation. This is as a consequence of the strategic review that has resulted in the creation…

Read More